Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
BackgroundThe effectiveness of Sacituzumab Govitecan (SG) for metastatic triple-negative breast cancer (mTNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on mTNBC from the Chinese and United States (US) perspective.MethodsA partitioned survival model was developed to compare...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.734594/full |
| _version_ | 1818691504997138432 |
|---|---|
| author | Jigang Chen Jigang Chen Mingyang Han Aihua Liu Aihua Liu Bo Shi |
| author_facet | Jigang Chen Jigang Chen Mingyang Han Aihua Liu Aihua Liu Bo Shi |
| author_sort | Jigang Chen |
| collection | DOAJ |
| description | BackgroundThe effectiveness of Sacituzumab Govitecan (SG) for metastatic triple-negative breast cancer (mTNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on mTNBC from the Chinese and United States (US) perspective.MethodsA partitioned survival model was developed to compare the cost and effectiveness of SG versus single-agent chemotherapy based on clinical data from the ASCENT phase 3 randomized trial. Cost and utility data were obtained from the literature. The incremental cost-effectiveness ratio (ICER) was measured, and one-way and probabilistic sensitivity analyses (PSA) were performed to observe model stability. A Markov model was constructed to validate the results.ResultsIn China, SG yielded an additional 0.35 quality-adjusted life-year (QALY) at an additional cost of Chinese Renminbi ¥2257842. The ICER was ¥6375856 ($924037)/QALY. In the US, SG yielded the same additional QALY at an extra cost of $175393 and the ICER was $494479/QALY. Similar results were obtained from the Markov model. One-way sensitivity analyses showed that SG price had the greatest impact on the ICER. PSA showed the probability of SG to be cost-effective when compared with chemotherapy was zero at the current willing-to-pay threshold of ¥217341/QALY and $150000/QALY in China and the US, respectively. The probability of cost-effectiveness of SG would approximate 50% if its price was reduced to ¥10.44/mg in China and $3.65/mg in the US.ConclusionSG is unlikely to be a cost-effective treatment of mTNBC at the current price both in China and the US. |
| first_indexed | 2024-12-17T12:42:57Z |
| format | Article |
| id | doaj.art-13e5e7eb23994a2cb72a7b917660f434 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-17T12:42:57Z |
| publishDate | 2021-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-13e5e7eb23994a2cb72a7b917660f4342022-12-21T21:47:52ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-10-011110.3389/fonc.2021.734594734594Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the USJigang Chen0Jigang Chen1Mingyang Han2Aihua Liu3Aihua Liu4Bo Shi5Beijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurosurgery, The Third Xiangya Hospital, Central South University, Changsha, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Breast Surgery, People’s Hospital of Qinghai Province, Xining, ChinaBackgroundThe effectiveness of Sacituzumab Govitecan (SG) for metastatic triple-negative breast cancer (mTNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on mTNBC from the Chinese and United States (US) perspective.MethodsA partitioned survival model was developed to compare the cost and effectiveness of SG versus single-agent chemotherapy based on clinical data from the ASCENT phase 3 randomized trial. Cost and utility data were obtained from the literature. The incremental cost-effectiveness ratio (ICER) was measured, and one-way and probabilistic sensitivity analyses (PSA) were performed to observe model stability. A Markov model was constructed to validate the results.ResultsIn China, SG yielded an additional 0.35 quality-adjusted life-year (QALY) at an additional cost of Chinese Renminbi ¥2257842. The ICER was ¥6375856 ($924037)/QALY. In the US, SG yielded the same additional QALY at an extra cost of $175393 and the ICER was $494479/QALY. Similar results were obtained from the Markov model. One-way sensitivity analyses showed that SG price had the greatest impact on the ICER. PSA showed the probability of SG to be cost-effective when compared with chemotherapy was zero at the current willing-to-pay threshold of ¥217341/QALY and $150000/QALY in China and the US, respectively. The probability of cost-effectiveness of SG would approximate 50% if its price was reduced to ¥10.44/mg in China and $3.65/mg in the US.ConclusionSG is unlikely to be a cost-effective treatment of mTNBC at the current price both in China and the US.https://www.frontiersin.org/articles/10.3389/fonc.2021.734594/fulleconomic evaluationSacituzumab Govitecanbreast cancerChinaUS |
| spellingShingle | Jigang Chen Jigang Chen Mingyang Han Aihua Liu Aihua Liu Bo Shi Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US Frontiers in Oncology economic evaluation Sacituzumab Govitecan breast cancer China US |
| title | Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US |
| title_full | Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US |
| title_fullStr | Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US |
| title_full_unstemmed | Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US |
| title_short | Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US |
| title_sort | economic evaluation of sacituzumab govitecan for the treatment of metastatic triple negative breast cancer in china and the us |
| topic | economic evaluation Sacituzumab Govitecan breast cancer China US |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.734594/full |
| work_keys_str_mv | AT jigangchen economicevaluationofsacituzumabgovitecanforthetreatmentofmetastatictriplenegativebreastcancerinchinaandtheus AT jigangchen economicevaluationofsacituzumabgovitecanforthetreatmentofmetastatictriplenegativebreastcancerinchinaandtheus AT mingyanghan economicevaluationofsacituzumabgovitecanforthetreatmentofmetastatictriplenegativebreastcancerinchinaandtheus AT aihualiu economicevaluationofsacituzumabgovitecanforthetreatmentofmetastatictriplenegativebreastcancerinchinaandtheus AT aihualiu economicevaluationofsacituzumabgovitecanforthetreatmentofmetastatictriplenegativebreastcancerinchinaandtheus AT boshi economicevaluationofsacituzumabgovitecanforthetreatmentofmetastatictriplenegativebreastcancerinchinaandtheus |